Ta Hsung Tung

Array ( [id] => 10333264 [patent_doc_number] => 20150218268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-06 [patent_title] => 'Use of TNFalpha Inhibitor for Treatment of Psoriasis' [patent_app_type] => utility [patent_app_number] => 14/681704 [patent_app_country] => US [patent_app_date] => 2015-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 23902 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14681704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10333265 [patent_doc_number] => 20150218269 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-06 [patent_title] => 'USE OF TNFALPHA INHIBITOR FOR TREATMENT OF PSORIATIC ARTHRITIS' [patent_app_type] => utility [patent_app_number] => 14/681713 [patent_app_country] => US [patent_app_date] => 2015-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 22767 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14681713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10693759 [patent_doc_number] => 20160039906 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'METHODS AND COMPOSITIONS FOR THE INHIBITION OF TRANSPLANT REJECTION' [patent_app_type] => utility [patent_app_number] => 14/679505 [patent_app_country] => US [patent_app_date] => 2015-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 35596 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14679505 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10693760 [patent_doc_number] => 20160039905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'B7-H4 FUSION PROTEINS AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/679497 [patent_app_country] => US [patent_app_date] => 2015-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 61112 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14679497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11936484 [patent_doc_number] => 20170240634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-24 [patent_title] => 'Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS' [patent_app_type] => utility [patent_app_number] => 15/125249 [patent_app_country] => US [patent_app_date] => 2015-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 24998 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15125249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10318561 [patent_doc_number] => 20150203564 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-23 [patent_title] => 'B7-H5, A Costimulatory Polypeptide' [patent_app_type] => utility [patent_app_number] => 14/645070 [patent_app_country] => US [patent_app_date] => 2015-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 11481 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14645070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10026111 [patent_doc_number] => 09067999 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2015-06-30 [patent_title] => 'Immunopotentiative composition' [patent_app_type] => utility [patent_app_number] => 14/638985 [patent_app_country] => US [patent_app_date] => 2015-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 13925 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14638985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10347528 [patent_doc_number] => 20150232533 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE' [patent_app_type] => utility [patent_app_number] => 14/617500 [patent_app_country] => US [patent_app_date] => 2015-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 17708 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14617500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12305937 [patent_doc_number] => 09938345 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-10 [patent_title] => Human antibodies to PD-L1 [patent_app_type] => utility [patent_app_number] => 14/603808 [patent_app_country] => US [patent_app_date] => 2015-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 3 [patent_no_of_words] => 30489 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14603808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10318576 [patent_doc_number] => 20150203579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-23 [patent_title] => 'Human Antibodies to PD-1' [patent_app_type] => utility [patent_app_number] => 14/603776 [patent_app_country] => US [patent_app_date] => 2015-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 42929 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14603776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11269256 [patent_doc_number] => 20160331803 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-17 [patent_title] => 'VISTA ANTAGONIST AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/111550 [patent_app_country] => US [patent_app_date] => 2015-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 18061 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 23 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15111550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12962683 [patent_doc_number] => 09873744 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2018-01-23 [patent_title] => Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying same [patent_app_type] => utility [patent_app_number] => 14/595668 [patent_app_country] => US [patent_app_date] => 2015-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 38 [patent_no_of_words] => 16312 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14595668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10333278 [patent_doc_number] => 20150218281 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-06 [patent_title] => 'SINGLE VARIABLE DOMAIN ANTIBODIES AGAINST OX40L, CONSTRUCTS AND THERAPEUTIC USE' [patent_app_type] => utility [patent_app_number] => 14/587042 [patent_app_country] => US [patent_app_date] => 2014-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 91457 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14587042 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10233239 [patent_doc_number] => 20150118234 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-30 [patent_title] => 'SUBSTANCE SPECIFIC TO HUMAN PD-1' [patent_app_type] => utility [patent_app_number] => 14/584664 [patent_app_country] => US [patent_app_date] => 2014-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 8624 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14584664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14246219 [patent_doc_number] => 10273301 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-30 [patent_title] => Anti-vista antibodies and fragments [patent_app_type] => utility [patent_app_number] => 15/107784 [patent_app_country] => US [patent_app_date] => 2014-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 94 [patent_no_of_words] => 22996 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 225 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15107784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10656193 [patent_doc_number] => 20160002336 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-07 [patent_title] => 'Methods of Modulating Immune Function' [patent_app_type] => utility [patent_app_number] => 14/456501 [patent_app_country] => US [patent_app_date] => 2014-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 72 [patent_figures_cnt] => 72 [patent_no_of_words] => 150417 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14456501 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10219458 [patent_doc_number] => 20150104451 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-16 [patent_title] => 'CTLA4 FUSION PROTEINS FOR THE TREATMENT OF DIABETES' [patent_app_type] => utility [patent_app_number] => 14/576990 [patent_app_country] => US [patent_app_date] => 2014-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 10849 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14576990 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10347550 [patent_doc_number] => 20150232555 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1' [patent_app_type] => utility [patent_app_number] => 14/576448 [patent_app_country] => US [patent_app_date] => 2014-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 20229 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14576448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10347550 [patent_doc_number] => 20150232555 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1' [patent_app_type] => utility [patent_app_number] => 14/576448 [patent_app_country] => US [patent_app_date] => 2014-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 20229 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14576448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10026103 [patent_doc_number] => 09067992 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-30 [patent_title] => 'Use of TNFα inhibitor for treatment of psoriatic arthritis' [patent_app_type] => utility [patent_app_number] => 14/563056 [patent_app_country] => US [patent_app_date] => 2014-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 22768 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14563056 [rel_patent_id] =>[rel_patent_doc_number] =>)